Ask HopeStage to help me review this study
This study may no longer be open, but we can help you understand it and find similar studies.
Study ID: ISRCTN42386710. We help you review the study, but cannot decide medical eligibility.
TerminatedISRCTN42386710
A double blind placebo controlled discontinuation of citalopram in adolescents with major depression
This study has public registry information. It focuses on depression and currently lists study information in Canada.
Depression, Mental healthOtherFrom 13 Years to 18 Years
Key information made simple
What is this study testing?
This study is testing whether a study medication may be useful for adolescents experiencing depression.
What would participation involve?
Participants may receive a study medication, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in Canada.
Who is it mainly for?
This study appears to be mainly for adolescents with depression. Because it involves minors, a parent or guardian may need to be involved.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, what role parents or guardians have in the process.
Your next step
The public record does not provide enough detail to summarize the visit format or participation steps clearly. Check the official source for the exact eligibility criteria, locations, contact details, and current recruiting status before taking any next step.
Questions to ask before joining
- What are the exact eligibility criteria, and what could exclude someone?
- How many visits, assessments, or follow-ups are expected, and over what period?
- What risks, side effects, practical burdens, or alternatives should be understood first?
- Who should be contacted to confirm locations, timing, compensation, and next steps?
Things to check before joining
Study start dateNot clearly listed
- Recruitment status
- Terminated
- Estimated enrollment
- Not clearly listed
- Sponsor
- Sunnybrook and Women's College Health Sciences Centre (Canada)
- Sponsor type
- University
- Study type
- Other
- Intervention type
- Other / unclear
- Study phase
- Not clearly listed
- Locations
- Canada
- Age range
- From 13 Years to 18 Years
- Official registry ID
- ISRCTN42386710
- Official title
- A double blind placebo controlled discontinuation of citalopram in adolescents with major depression
- Official source
- Official registry link
Ask HopeStage to help me review this study
This study may no longer be open, but we can help you understand it and find similar studies.
Study ID: ISRCTN42386710. We help you review the study, but cannot decide medical eligibility.
For you
Taking part may help improve understanding of your condition.
It requires a lighter follow-up, often with questionnaires or check-ins.
Not medical advice
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
Questions about this study
What is this study trying to understand?
This study is exploring behavioral or lifestyle intervention for people with depression. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Why is the study type not clearly categorized?
The study type is not clearly categorized in the public registry. Focus on the objective, required tasks, visits, any intervention, and eligibility criteria, then ask the study team to confirm.
Who might this study be for?
This study may concern people with depression; age range: From 13 Years to 18 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
The public registry does not clearly describe all participation steps. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
Will I need to change, stop, or stabilize my current treatment?
The public registry appears to mention rules about current treatment, stability, stopping treatment, or dose changes. Do not change your treatment for a study without medical guidance. Ask the study team and your clinician what is required, what is not allowed, and how safety is monitored.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Sunnybrook and Women's College Health Sciences Centre (Canada), which appears to be a university. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The registry indicates that this study is not currently recruiting. Check the official registry for the reason and latest status.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
TerminatedNCT02155972
The Safety and Effectiveness of Probiotic Supplementation on Depression in bipolarity
This study has public registry information. It focuses on bipolarity and currently lists study information in Canada.
TerminatedISRCTN93153882
Treatment outcome improvements by using Rx Report (a pharmacogenomic test) in depressive disorder patients
This study has public registry information. It focuses on depression and currently lists study information in Canada.
TerminatedNCT05169710
An Investigational Drug for depression
This study has public registry information in the United States, in Canada, in Bulgaria, .... It is testing an Investigational Drug for depression.